In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Jian Xie Biography and Net Worth

COO of Fulgent Genetics

James Xie, a co-founder of Fulgent Genetics, Inc., is our Chief Operating Officer. Prior to joining Fulgent, Mr. Xie served as the Senior Vice President of Cogent Inc., a publicly traded biometric identification service and product company from 1996 until 2011. As Chief Operating Officer of Fulgent, Mr. Xie is responsible for managing all global operations, product vision and product engineering. He is focused on unifying all departments to maximize efficiency, drive sustainable growth and inspire continuous innovation.

He received his B.A. in Engineering from Chongqing University in 1987, and has both an M.S. in Industrial Engineering and an M.S. in Computer Science from the University of New South Wales in 1992.

In his free time, he also is a flight instructor for single-engine, multi-engine, and instrument airplanes. He holds a Commercial Pilot’s License (CPL) and Airline Transport Pilot’s License (ATPL).

What is Jian Xie's net worth?: The estimated net worth of Jian Xie is at least $6.10 million as of August 27th, 2024. Mr. Xie owns 342,764 shares of Fulgent Genetics stock worth more than $6,097,772 as of November 14th. This net worth approximation does not reflect any other assets that Mr. Xie may own. Additionally, Mr. Xie receives an annual salary of $868,740.00 as COO at Fulgent Genetics. Learn More about Jian Xie's net worth.
How old is Jian Xie?: Mr. Xie is currently 58 years old. There are 4 older executives and no younger executives at Fulgent Genetics. The oldest executive at Fulgent Genetics is Mr. Ming Hsieh, Chairman & CEO, who is 68 years old. Learn More on Jian Xie's age.
What is Jian Xie's salary?: As the COO of Fulgent Genetics, Inc., Mr. Xie earns $868,740.00 per year. There are 2 executives that earn more than Mr. Xie. The highest earning executive at Fulgent Genetics is Mr. Ming Hsieh, Chairman & CEO, who commands a salary of $2,310,000.00 per year. Learn More on Jian Xie's salary.
How do I contact Jian Xie?: The corporate mailing address for Mr. Xie and other Fulgent Genetics executives is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. Fulgent Genetics can also be reached via phone at (626) 350-0537 and via email at [email protected]. Learn More on Jian Xie's contact information.
Has Jian Xie been buying or selling shares of Fulgent Genetics?: Jian Xie has not been actively trading shares of Fulgent Genetics in the last ninety days. Most recently, Jian Xie sold 715 shares of the business's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $22.83, for a transaction totalling $16,323.45. Following the completion of the sale, the chief operating officer now directly owns 342,764 shares of the company's stock, valued at $7,825,302.12. Learn More on Jian Xie's trading history.
Who are Fulgent Genetics' active insiders?: Fulgent Genetics' insider roster includes John Bolger (Director), Hanlin Gao (Insider), Ming Hsieh (Chairman & CEO ), Paul Kim (CFO), and Jian Xie (COO). Learn More on Fulgent Genetics' active insiders.
Are insiders buying or selling shares of Fulgent Genetics?: During the last twelve months, insiders at the sold shares 9 times. They sold a total of 32,464 shares worth more than $850,501.04. The most recent insider tranaction occured on August, 27th when insider Hanlin Gao sold 563 shares worth more than $12,853.29. Insiders at Fulgent Genetics own 31.8% of the company. Learn More about insider trades at Fulgent Genetics.
Information on this page was last updated on 8/27/2024.

Jian Xie Insider Trading History at Fulgent Genetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/27/2024	Sell	715	$22.83	$16,323.45	342,764
12/11/2023	Sell	22,000	$26.52	$583,440.00	363,124
12/4/2023	Sell	1,779	$27.57	$49,047.03	385,124
11/16/2023	Sell	1,617	$27.25	$44,063.25	386,903
9/7/2023	Sell	1,492	$31.41	$46,863.72	416,022
8/17/2023	Sell	1,307	$33.88	$44,281.16	417,514
6/2/2023	Sell	1,433	$40.30	$57,749.90	425,794
11/30/2022	Sell	685	$34.39	$23,557.15	430,074
8/30/2022	Sell	675	$44.18	$29,821.50	309,729
5/16/2022	Sell	1,269	$53.38	$67,739.22	329,701
11/29/2021	Sell	636	$95.42	$60,687.12
8/30/2021	Sell	622	$91.25	$56,757.50	311,195
8/16/2021	Sell	1,223	$95.12	$116,331.76
5/28/2021	Sell	647	$73.46	$47,528.62	337,394
5/25/2021	Sell	2,000	$72.21	$144,420.00	338,041
5/20/2021	Sell	1,000	$74.48	$74,480.00	341,041
5/18/2021	Sell	931	$70.71	$65,831.01	341,041
3/9/2021	Sell	62,000	$102.65	$6,364,300.00	345,476
12/2/2020	Sell	1,000	$46.00	$46,000.00	434,085
11/30/2020	Sell	3,396	$43.22	$146,775.12	434,085
11/17/2020	Sell	3,706	$45.34	$168,030.04	447,585
8/28/2020	Sell	441	$30.82	$13,591.62	601,295
8/3/2020	Sell	1,976	$27.86	$55,051.36	603,712

Jian Xie Buying and Selling Activity at Fulgent Genetics

Fulgent Genetics Company Overview

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Today's Range

Now: $17.79

$17.65

$18.60

50 Day Range

MA: $20.85

$18.42

$22.91

2 Week Range

Now: $17.79

$17.65

$30.68

Volume

294,612 shs

Average Volume

181,668 shs

Market Capitalization

$544.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Trump Wins… But Elon Says Get Ready to Brace

From Genesis Gold Group | Ad

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

Jian Xie Biography and Net Worth

What is Jian Xie's net worth?

How old is Jian Xie?

What is Jian Xie's salary?

How do I contact Jian Xie?

Has Jian Xie been buying or selling shares of Fulgent Genetics?

Who are Fulgent Genetics' active insiders?

Are insiders buying or selling shares of Fulgent Genetics?